IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Vanta Bioscience Ltd.
Issue Open Date 25-Sep-17  
Issue Closing Date 27-Sep-17  
Application Money 100  
Allotment Money  
Price Band 50 -  
Minimium Application No. 3000  
Issue Size (Shares) 1512000  
Market Lot 1.00  
Objective
The objects of the Net Proceeds (as defined below) of the Issue are:1. Augmenting additional working capital requirements2. General Corporate Purposes
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors       NA  
Qualified Institutional Buyers       NA  
Retail Individual Investors       NA  
Business Description
OverviewVanta Bioscience Limited (VBS) is a preclinical contract research organization, offering a host of preclinical safetyassessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech,Agrochemicals, Cosmetics
more...
Promoter's Holding
Total Share Capital    
Offered to Public    
Promoter's Holding (Pre-Issue)    
Promoter's Holding (Post-Issue)    
Address
No.02/ G/308/ G
No.3/ F F/ S F/1-20-248
Umajay Complex
Rasoolpura
Secunderabad
Hyderabad ,
Telangana ,
500003
Phone: 040-6657 5454 / 2790 3226
Email: cs@vantabio.com / info@vantabio.com
Website: www.vantabio.com
Registrar
Bigshare Services Pvt Ltd
G 10 Left Wing Amruta Village
Opp: Yashoda Hospital
Raj Bhavan Road
Somajiguda
Hyderabad
Listed at
BSE
Lead Manager
Inventure Merchant Bankers Services Pvt Ltd.
Promoters
Chandrasekhar Rao Simhadri
Dopesh Raja Mulakala
Karishma Mulakala
Mohan Krishna Mulakala
Pradeep Chowdary
Sajan Kiran Mulakala
Shravan Chintapatla
Soumya Simhadri
Vyasmurti Madhavrao Shingatgeri
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Awareness & Information | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.